Download Free Underactive Thyroid Clinical Trials Software



Findings In this meta-analysis of 21 randomized clinical trials including 2192 participants with subclinical hypothyroidism, thyroid hormone therapy was not significantly associated with improvements in general quality of life (standardized mean difference, −0.11) or thyroid-related symptoms (standardized mean difference, 0.01).

  • Trials of combination therapy are supported by the American Thyroid Association, but clinical studies are mixed on whether this approach works, Bianco said. Subjectively, some patients report.
  • The study medication (levothyroxine and matching placebo) was supplied by Merck KGaA at no cost. Merck played no role in designing, analyzing, or reporting the trial. Clinical Trial Information: The trial was registered on ClinicalTrials.gov numbers NCT01660126 (TRUST Thyroid trial) and NCT02491008 (Skeletal outcomes). Additional Information.
2017-02-39 on Wed 8Feb

Every day over one million people in the UK take the thyroid hormone Levothyroxine sodium (L-T4) for an underactive thyroid (hypothyroidism). The goal of therapy is to

  • restore well-being
  • normalise the serum thyroid-stimulating hormone (TSH) level
Clinical

- TSH being the hormone which is secreted by the pituitary gland and which regulates thyroid hormone (thyroxine (T4) and triiodothyronine (T3)) production.

Most patients respond satisfactorily but a minority of treated individuals experience persistent symptoms despite adequate biochemical correction. The care of such individuals is challenging and remains the subject of considerable public interest.

Diagnosis and Evidence

The diagnosis of primary hypothyroidism is based on the clinical features of hypothyroidism supported by biochemical evidence of an elevated serum TSH together with low free T4 (overt hypothyroidism).

The earliest evidence of an underactive thyroid (hypothyroidism) is an elevated serum TSH.

About serum TSH levels

Underactive Thyroid Men

There has been a growing controversy about the upper limit of the reference range for serum TSH and at what point patients actually benefit from thyroid hormone replacement.

To establish a “normal” reference range in the first place we look at large group of people who do not have thyroid disease and are otherwise well. By convention this only comprises 95% of a reference population.

Therefore it is understood that, 2.5% of ‘normal’ individuals will fall above the reference range and 2.5% will fall below the range.

By doing this the reference range for serum TSH in thyroid- disease- free individuals is accepted as between 0.4 and 4.0 mU/l.

Studies and Trials

Studies addressing the relationship between symptoms suggestive of thyroid hormone deficiency and the biochemical finding of a mildly elevated TSH and a normal T4 (subclinical hypothyroidism) have produced conflicting results.

What’s more, in randomised controlled trials, there is inconsistent evidence for the benefit of thyroid hormone treatment in subclinical hypothyroidism.

Download Free Underactive Thyroid Clinical Trials Software

The conclusion is that Primary hypothyroidism should not be diagnosed in individuals with a serum TSH within the population reference range and who have intact pituitary function.

Thyroid Function

The healthy thyroid produces mainly T4 and much smaller amounts of the physiologically more active T3.

Approximately 80% of T3 is provided by conversion of T4 to T3 with the remaining 20% of the T3 secreted direct from the thyroid.

In contrast, people with hypothyroidism are treated with T4 alone, so all of their T3 is produced as a result of conversion from T4.

It has been suggested that one reason why some people are not happy with L-T4 treatment is that they are not getting their supply of T3 in a physiological way, as all of it is coming from the conversion from T4.

So would patients be better off with potentially more physiological combination treatment with synthetic human L-T4 and L-T3 than with L-T4 monotherapy?

In considering this The British Thyroid Association recently published a peer-reviewed position statement in the leading UK endocrine journal Clinical Endocrinology on the management of primary hypothyroidism. See here

This is based on a review of the recently published positions of the American Thyroid Association (ATA) and the European Thyroid Association (ETA); upon current literature and upon the best principles of good medical practice.

This statement has been endorsed by the Association of Clinical Biochemistry (ACB); the British Thyroid Foundation (BTF); the Royal College of Physicians (RCP); and the Society for Endocrinology (SFE).

In brief the conclusion is that the benefits of combination therapy with LT-4 and LT-3 are still unproven, and the potential for harm exists with unregulated use of unapproved therapies especially the lack of long term L-T3 safety data and the unavailability of L-T3 formulations which accurately mimic natural physiology.

Our advice to the medical community

People may now have high expectations about how energetic they should feel, but that does not mean that tiredness and depression should be ignored.

It has been demonstrated that up to one-quarter of the healthy population have the non-specific symptoms associated with thyroid failure such as lethargy and weight gain. However, patients should be thoroughly evaluated for other modifiable conditions such as other autoimmune conditions and mood disorders.

This may mean that in some cases a retrospective review of the original diagnosis of hypothyroidism may prove to be necessary.

Symptom and lifestyle management support should be provided and further dose adjustments may be required.

L-T4 is considered the most effective hormone replacement that has yet been devised for endocrine conditions, but there are undoubtedly people who fall outside the current treatment model.

Animal-derived products that contain T4 and T3 are not physiological and are not the answer in the longer term, but we do need to find ways to ensure that all our patients with hypothyroidism feel the full benefits of replacement therapy.

Although every effort is made to ensure that all health advice on this website is accurate and up to date it is for information purposes and should not replace a visit to your doctor or health care professional.

As the advice is general in nature rather than specific to individuals the BTA cannot accept any liability for actions arising from its use nor can he be held responsible for the content of any pages referenced by an external link.

Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Jacqueline Jonklaas, Antonio Carlos Bianco, Anne Cappola, Francesco S Celi, Eric Fliers, Heike Heuer, Elizabeth A McAninch, Lars C Moeller, Birte Nygaard, Anna M Sawka, Torquil Watt, Colin Dayan
Thyroid: Official Journal of the American Thyroid Association 2020 December 4
33276704
Background Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods The ATA, BTA and ETA held a joint conference on November 3rd 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from twelve content experts. Following the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and following comments from ATA/BTA/ETA members. Results Of 34 Consensus Statements available for voting 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 mcg/kg of levothyroxine daily, use of twice daily liothyronine or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized, placebo-controlled, adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion This manuscript summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.

Full Text Links

Underactive
We have located links that may give you full text access.

Additional links

PubMed

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Trending Papers

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection.Clinical Microbiology Reviews 2021 March 17, 34 (2)
Long-term follow-up of recovered patients with COVID-19.Lancet 2021 January 8

Best Foods For Underactive Thyroid

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome.European Journal of Clinical Microbiology & Infectious Diseases 2021 January 3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.New England Journal of Medicine 2020 December 10
Evaluating the Efficacy of COVID-19 Vaccines.Clinical Infectious Diseases 2020 December 19

What Causes Underactive Thyroid

Hematologic disorders associated with COVID-19: a review.Annals of Hematology 2021 January 7
Download free underactive thyroid clinical trials software 10

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Underactive Thyroid Test

Read also provides personalized recommendations to keep you up to date in your field.

Symptoms Of A Underactive Thyroid

New to Read